Treatment of Rheumatoid Arthritis with Poor Prognostic Factors When Methotrexate Is Appropriate
Clinical Scenario
This protocol addresses patients with rheumatoid arthritis who have no contraindication or early intolerance to methotrexate and who present with one or more poor prognostic factors indicating elevated risk of persistent disease activity or structural damage.
Poor Prognostic Factors Covered
The protocol applies when any of the following findings are present:
- Presence of RF (rheumatoid factor) and/or ACPA, especially at high levels
- Persistently moderate or high disease activity despite csDMARD therapy
- High swollen joint count
- High acute phase reactant levels
- Presence of early erosions
- Failure of 2 or more csDMARDs
Treatment Approach (Partial Overview)
The protocol centres on methotrexate as the cornerstone conventional synthetic DMARD, combined with a short course of glucocorticoids as bridging therapy. Full dosing, escalation, and tapering details are available in the structured protocol.
Treatment Targets
The goal is at least 50% improvement in disease activity within 3 months, progressing to sustained remission or low disease activity by 6 months. Remission is defined by a validated composite measure including swollen joint count, tender joint count, CRP, and patient global assessment.
References
DOI: 10.1136/ard-2022-223356
- MTX should be part of the first treatment strategy.
- Presence of RF and/or ACPA, especially at high levels.
- Presence of early erosions.
- Failure of 2 or more csDMARDs.
- Short-term glucocorticoids should be considered when initiating or changing csDMARDs, in different dose regimens and routes of administration, but should be tapered and discontinued as rapidly as clinically feasible.
- Treatment should be aimed at reaching a target of sustained remission or low disease activity in every patient.
- The general treat-to-target approach focuses on at least a 50% improvement in disease activity within 3 months and the attainment of the main treatment target at about 6 months.
View source ↗